Developing an early cost-effectiveness model to identify economic drivers, pricing potential, and evidence gaps

Our client had Phase 2 clinical trial data and needed to understand the key health economic drivers in their disease area and the strength of the value proposition for potential HTA submissions. Additionally, they needed to generate an evidence generation plan that would support their cost-effectiveness analysis.

We developed a bespoke cost-effectiveness model based on the design of the Phase 2 trial. The model was designed allow sensitivity analyses which would explore disease-specific drivers of cost-effectiveness. Based on this, we recommended that additional PRO data be collected at Phase 3.

The client was able to use the early model to assess pricing for their technology and understand areas in which a lack of data was likely to have a negative effect on their likelihood of reimbursement. They also heeded our recommendation to collect additional PRO data in their Phase 3 trial.